Recon

FDA Wrestles With Undoing Decision

WASHINGTON—The Food and Drug Administration is struggling to determine whether it has authority to re-evaluate a knee device that it had earlier cleared, raising questions about the scope of the agency’s powers and injecting fresh uncertainty into the medical-devices sector.

The questions have emerged ahead of an FDA meeting of outside orthopedic surgery experts Tuesday. An agency committee will re-examine the Menaflex knee-repair device made by ReGen Biologics Inc..

The head of the FDA’s device division had approved the knee device in December 2008 after repeated objections from FDA scientists and managers. After an Wall Street Journal article last year …

TO CONTINUE READING- http://online.wsj.com/article/SB10001424052748704454004575136050338352766.html?mod=dist_smartbrief <SUBSCRIPTION REQUIRED>

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close
Themed By teapots